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Foot-and-mouth disease virus (FMDV) is a highly infectious member of the Picornaviridae inducing an acute disease
of cloven-hoofed species. Vaccine-induced immune protection correlates with the presence of high levels of
neutralizing antibodies but also opsonising antibodies have been proposed as an important mechanism of the
immune response contributing to virus clearance by macrophages and leading to the production of type-I
interferon (IFN) by plasmacytoid dendritic cells (pDC). The present study demonstrates that the opsonising antibody
titres mediating enhanced IFN-α responses in pDC were similar to neutralizing titres, when antigenically related
viruses from the same serotype were employed. However, sera cross-reacted also with non-neutralized isolates of
multiple serotypes, when tested in this assay. Both uncomplexed virus and immune complexed virus stimulated
pDC via Toll-like receptor 7. An additional finding of potential importance for strain-specific differences in virulence
and/or immunogenicity was that pDC activation by FMDV strongly differed between viral isolates. Altogether, our
results indicate that opsonising antibodies can have a broader reactivity than neutralizing antibodies and may
contribute to antiviral responses induced against antigenically distant viruses.Introduction
Foot-and-mouth disease virus (FMDV) is a highly conta-
gious infectious agent inducing disease of cloven-hoofed
animals including cattle, swine, goats and sheep. Due to
the significant economic impact on livestock, a tight dis-
ease control is required. However, its high mutation rate
contributes to immune escape and the presence of seven
serotypes (O, A, C, Asia-1, South African Territories 1,
2 and 3) each containing a large variety of isolates
with high antigenic variability.
Current conventional vaccines, consisting of inacti-
vated virus, provide a short-term serotype specific pro-
tection. However, vaccination does not induce protection
against all isolates within one serotype [1]. Protection is
related to the presence of high level of neutralizing anti-
body in serum. However, animals with low levels of neu-
tralizing antibodies can also be protected [2,3].* Correspondence: artur.summerfield@ivi.admin.ch
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reproduction in any medium, provided the orFurthermore, non-neutralizing concentrations of mono-
clonal antibodies (mAb) can induce protection in mice
[4]. Thus, other mechanisms than neutralization could
be involved in protection. It has been shown that opson-
isation of FMDV enhances phagocytosis by monocytes
and macrophages in vitro [5]. More recent in vivo data
emphasize the potential role of opsonising antibodies in
a mouse model, in which protection was mediated in a
macrophage-dependent manner [6]. While these studies
indicate that immune complexed virus could be elimi-
nated after phagocytosis by macrophages bearing Fc
receptors (FcR), other studies also indicate a participation
of dendritic cells (DC), at least in vitro. Immune com-
plexes induce the activation of porcine plasmacytoid DC
(pDC) resulting in the production of interferon (IFN)-α
[7]. The possible involvement of opsonising antibodies
in FMDV immunity was also confirmed with bovine
pDC [8].
PDC represent 0.1–0.5% of porcine peripheral blood
mononuclear cells (PBMC), with similar functionalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[9]. They are characterized by producing high amount of
antiviral type-I IFN in response to a wide range of
pathogens. pDC activation is mediated by sensing
pathogen-associated molecular patterns (PAMP) through
pattern recognition receptors (PRR). By expressing PRR,
such as Toll-like receptors (TLR) and C-type lectin
receptors, pDC contribute to the innate and adaptive
antiviral immunity [10]. Antibody-dependent FMDV
entry in pDC occurs via the FcγRII receptor (CD32) [7],
linking pDC to the adaptive immunity [11].
Considering the possible importance of opsonising anti-
bodies and pDC in the protection against FMDV, the main
aim of this study was to characterize the relationship be-
tween neutralizing and opsonising activities of polyclonal
sera from immunized pigs. Although neutralization and
opsonisation occurred at similar serum dilutions when
antigenically related viruses were employed, opsonisation
also occurred in the absence of neutralization and across
different serotypes. We also discovered differences in the
ability of various FMDV isolates to activate pDC.
Materials and methods
Antibodies and phenotyping
For pDC enrichment, monoclonal antibodies against fol-
lowing cell surface markers were used: CD172a (mAb 74-
22-15A), CD14 (mAb CAM36A), CD3 (mAb 8E6) and
CD4 (mAb PT90A). For phenotyping, mAb against
CD172a and CD4 were used. Hybridoma for mAb 74-22-
15A was kindly provided by Dr A. Saalmüller (Veterinary
University, Vienna, Austria). mAbs CAM36A, 8E6 and
PT90A were purchased from VMRD (Pullman, WA, USA).
Cell culture
Unsorted and sorted (see below) PBMC were cultured in
Dulbecco’s modified Eagle’s minimal essential medium
(DMEM) plus GlutaMAX™-I (GIBCO, Life Technologies,
Basel, Switzerland) supplemented with 20 μM of β-
mercaptoethanol (Life Technologies) at 39°C at 6% CO2.
Baby Hamster Kidney (BHK) 21 cells were grown in Glas-
gow’s minimum essential medium (GMEM, Life Tech-
nologies) supplemented with 5% v/v Fetal Bovine Serum
(FBS, South America Origin, Biowest, Nuaillé, France).
For virus preparation and serum neutralization test, cells
were cultured in FBS-free GMEM at 37°C, 6% CO2.
Enrichment of pDC and purity check
Blood was collected alternatively from a total of 10 spe-
cific pathogen-free (SPF) pigs of 2–24 months old kept
at our institute. PBMC were isolated from citrated blood
using Ficoll Paque (1.077 g/L, Amersham Pharmacia
Biotech AG, Dubendorf, Switzerland) density gradient
[12]. For pDC enrichment, PBMC were separated using
magnetic sorting system (MACS) with depletion (LD)and selection (LS) columns (Miltenyi Biotech GmbH,
Bergisch-Gladbach, Germany). pDC were enriched either
using CD172a positive selection with LD columns or by
a first depletion of CD14+ cells with a subsequent posi-
tive selection for CD172a+ cells. Alternatively, PBMC
were isolated using Ficoll Paque and Optiprep (60% w/v
solution of oidixanol in water, Sigma-Aldrich, Saint
Louis, MO, USA) density gradients followed by a deple-
tion of CD3+ cells and a final enrichment of CD4+ cells
[13]. Purity of the sorted population was verified by flow
cytometry detection, after staining with anti-CD172a
and anti-CD4 mAbs and isotype-specific R-phycoeryth-
rin (R-PE) and fluorescein isothiocyanate (FITC) conju-
gates (Southern Biotechnology Associates, Birmingham,
AL, USA) as described [14]. The pDC population
was identified as CD4highCD172alow cells by flow
cytometry [15].Virus preparation
Isolates of FMDV were propagated in BHK-21 cells as
previously described [16] and viral titres were deter-
mined by end-point titration on BHK-21 cells [5]. O
UKG 2001, C1 Noville, O Bulgaria 1/91, O VietNam 7/
97, A Brazil 10/93, A Turkey/99 and Asia-1 Turkey/99
were kindly provided by Drs. Nigel Ferris and Satya Par-
ida (Institute for Animal Health, Pirbright, UK). In order
to avoid heparin sulphate adaptation of the virus, the
isolates were not passaged more than three times in
BHK-21 cells [17]. Mock antigen was prepared from un-
infected BHK-21 cells in the same manner as FMDV.Production of immune serum
Two SPF pigs were immunized intra-muscularly with
the full-dose of a monovalent FMDV vaccine consisting
of inactivated type-O Manisa antigen (Merial, Lyon,
France). Animals received prime injection at day 0 and a
booster at day 21. At day 0, 14, 21, 28, and 42, blood
samples were taken and serum prepared for storage at
-20°C. Serum samples from a naïve animal of the same
litter were used as controls. In certain experiments,
serum was complement inactivated by heat-treatment at
56°C for 30 min.Serum neutralization test
Serial dilutions of heat-treated serum were incubated at
room temperature (RT) for 30 min with 100 TCID50 of
FMDV isolate to form immune complexes in final vol-
ume of 100 μL/well and then added to confluent BHK-
21 cells, grown in 96-well plate for 3 days. The
neutralization titre was calculated according to Kaerber
[18] based on FMDV-induced cytopathogenic effect
(CPE).
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pathway
Isolated PBMC and sorted cells (4 × 106cells/mL) were sti-
mulated in 100 μL of serum-free medium with FMDV,
FMDV/immune serum mixture or FMDV/naïve serum
mixture. Sera were used either untreated or heat-treated.
FMDV/serum mixtures were previously formed for 30 min
at 39°C. As control, cells were stimulated with CpG D32
(10 μg/mL, Invitrogen, Basel, Switzerland). Influenza virus
strain PR8 was employed to test the specificity of the TLR7
inhibitor IRS661 (5’-TGCTTGCAAGCTTGCAAGCA-3’).
As control, the oligonucleotide (ODN) sequence (5’-
TCCTGCAGGTTAAGT-3’) was used [19]. IRS661 and
Ctrl-ODN were purchased from Eurofins MWG Operon
(Ebersberg, Germany). Influenza virus was grown on
10 days embryonated chicken eggs and titrated as previ-
ously described [20]. pDC activation by influenza virus
employed an multiplicity of infection (MOI) of 10 TCID50/
cell [21]. Supernatants from enriched pDC were harvested
after 24 h and IFN-α was detected by specific ELISA as
described [14]. Data were collected using a VersaMax pho-
tometer with SOFTmax Pro software.
Statistical analysis
Significant differences were determined with SigmaPlot
v11 using the Sum Rank Test (P < 0.005).
Results
Impact of enrichment method on pDC activation by
FMDV
We previously documented that pDC activation by
FMDV occurs only in presence of specific antibodies [7].
However, these experiments were performed with pDC,
which were only enriched about ~5-10 fold from PBMC
using a CD172a positive selection by magnetic cell sort-
ing (Figure 1A). Therefore, more efficient purification
methods were evaluated in this study. pDC are non-T
cells (CD3 ) [22] and are found within the CD172a-
lowCD4highCD14 PBMC [15]. Based on this, PBMC were
first depleted from CD14+ monocytes and subsequently
enriched using CD172a. This resulted in a frequency of
3-5% of pDC (~20 fold enrichment), depending on the
experiment. A third protocol employed a CD3 depletion
and subsequent CD4 enrichment of PBMC resulting in a
pDC population of 15-60% (Figure 1A).
Type A CpG oligonucleotides, like CpG ODN D32, are
potent activators of IFN-α secretion from porcine pDC
[14] and were employed as positive controls. While CpG
induced only a few hundred units of IFN-α from unpuri-
fied PBMC, after magnetic cell sorting the production
was increased by ~10 fold but with little differences be-
tween the different purification protocols (Figure 1B).
This contrasted with pDC stimulation by FMDV O UKG
2001. As reported previously, no stimulation of PBMC orCD172a-enriched PBMC in terms of IFN-α production
was observed. Only the protocols employing either the
CD14-depleted and subsequent CD172a-enriched PBMC
or the CD3-depleted and subsequently CD4-enriched
PBMC permitted the induction of IFN-α after stimula-
tion with FMDV O UKG 2001 (Figure 1C). It is import-
ant to note that these responses were in the range of 100
times lower than those seen after CpG stimulation.
As the IFN-α level was not significantly higher when
CD3-depleted/CD4-enriched PBMC were compared
with the CD14-depleted/CD172a-enriched PBMC while
the number of cells obtained upon enrichment was
higher with the latter protocol, the CD14 depletion/
CD172a enrichment method was employed for the fol-
lowing experiments.
pDC activation by FMDV varies between different FMDV
isolates
While testing for the capacity of different FMDV isolates
to activate pDC, we found remarkable differences, exem-
plified for three different FMDV isolates employed at
MOIs of 1, 2.5 and 5 TCID50/cell (Figure 2A). At the
lowest MOI, IFN-α was only detected after stimulation
with O Bulgaria 1/91. With the MOI of 2.5 TCID50/cell,
Asia-1 Turkey 99 induced a weak response and O Bul-
garia 1/91 a relatively strong response. These responses
were further increased when the virus dose was doubled,
but O UKG 2001 remained a poor IFN-α inducer
(Figure 2A). Considering these results, we tested more
FMDV isolates for their ability to activate pDC at an
MOI of 5 TCID50/cell (Figure 2B). The results confirmed
that the ability of FMDV to activate pDC varies consid-
erably, even within one serotype. Relatively strong indu-
cers were O Bulgaria 1/91 and Asia-1 Turkey 99; weak
inducers were O VietNam 7/97 and O UKG 2001, and
the most inefficient inducers were C1 Noville, A Brazil
10/93 and A Turkey 99.
Effects of a neutralizing immune serum raised against
serotype O on strong and weak IFN-α inducing FMDV O
serotype isolates
As previous studies used purified subtype-specific anti-
bodies [7] or high concentration of serotype-specific im-
mune serum [8] to form FMDV immune complexes, we
were interested to determine the relationship between
serum concentration and IFN-α enhancement. Opson-
isation of FMDV O UKG 2001 by a serum with a
neutralization titre (NT) of 4.1 log10 at dilutions below 1
log10 did not induce pDC activation (Figure 3A). In fact,
such high serum concentrations showed suppressive
effects on pDC stimulation by FMDV, which were inde-
pendent on the immune status of the donor animal (data
not shown). They were therefore omitted in the







































































































































Figure 1 Enrichment methods for porcine pDC: purity and impact on pDC activation by FMDV. A. CD172a/CD4 plot of unsorted PBMC,
CD172a-enriched PBMC, CD14-depleted and subsequently CD172a-enriched PBMC, CD3-depleted and subsequently CD4-enriched PBMC. pDCs
were gated based on their CD4highCD172alow phenotype, and their percentage is indicated. B and C. IFN-α responses of PBMCs and sorted
populations shown in (A). The cells were stimulated for 24 h at 39°C with 10 μg/mL of CpG D32, medium (B), or FMDV O UKG 2001 at a MOI of 5
TCID50/cell (C). IFN-α in the supernatants was detected by ELISA. The bars represent the mean value of triplicates and the errors bars show the
standard deviation. The data are representative for two independent experiments.
A BO UKG 2001 O Bulgaria 1/91
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Even with an MOI as low as 0.5 TCID50/cell, immune























Figure 2 pDC activation by FMDV varies between different
FMDV isolates. IFN-α responses of enriched pDCs (CD14-depletion/
CD172a-enrichment) stimulated by different FMDV isolates at various
MOIs (A) or with various FMDV isolates at an MOI of 5 TCID50/cell
(B). After 24 h, IFN-α was measured in the supernatants by ELISA.
The bars represent the mean value of triplicates and the errors bars


























































NT : 4.1 NT : 3.1
Figure 3 Effects of a neutralizing immune serum raised against
serotype O on strong and weak IFN-α inducing FMDV serotype
O isolates. IFN-α responses induced by various MOIs of FMDV O
UKG 2001 (A) or O Bulgaria 1/91 (B) pre-incubated with anti-O
Manisa immune serum at the indicated dilutions. Immune
complexes were allowed to form by incubating at 39°C for 30 min,
before addition to enriched pDC (CD14-depletion/CD172a-
enrichment). After 24 h of culture, IFN-α was quantified by ELISA.
The mean value of triplicates and standard deviations of triplicate
cultures are shown. The data are representative of three
independent experiments. The neutralization titres (NT) of the serum
against the two viruses is expressed in log10 of serum dilution.
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high IFN-α inducing FMDV isolate (Figure 2B). The
serum employed showed a NT of 3.1 log10 against this
virus. With O Bulgaria 1/91 at an MOI of 1 TCID50/mL,
immune serum enhanced pDC-derived IFN-α response
in the expected concentration-dependent manner with
maximum IFN-α level at a serum dilution of 1.8 log10
and a gradual loss of the enhancing activity with further
serum dilutions (Figure 3B). In contrast, when O Bul-
garia 1/91 was used at MOIs of 2.5 and 5 TCID50/cell,
this serum concentration-dependent relationship was
not observed (Figure 3B). In particular, with the highest
virus dose a clear enhancement of IFN-α responses was
not observed. We concluded that low MOIs have to be
employed to measure antibody-dependent enhancement
of IFN-α responses by pDC when high IFN-α-inducing
FMDV isolates are used.
Immune complex-induced pDC activation is complement
independent
Results obtained with various serum dilutions and various
FMDV isolates indicated that other serum factors than
specific immunoglobulin (Ig) influenced pDC activation.
For this reason a naive serum was titrated in parallel to
the immune serum, and the possible impact of comple-
ment tested by heat-treatment of the sera before forming
immune complexes. Figure 4 shows a representative ex-
periment in which immune serum enhanced the IFN-α re-
sponse induced by FMDV O UKG 2001 relative to naive
serum. Nevertheless, this enhancement was only clear at a
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Figure 4 Immune complexes-induced pDC activation is
complement independent. IFN-α responses of enriched pDC
(CD14-depletion/CD172a-enrichment) stimulated by FMDV O UKG
2001 (MOI of 1 TCID50/cell) pre-incubated with serum from a naïve
and O Manisa-immune pig. The serum was either untreated (A) or
heat-treated at 56°C for 30 min (B). After 24 h, IFN-α in the
supernatants was measured by ELISA. The mean value and the
standard deviations of triplicates cultures are shown. The data are
representative of three independent experiments.treated sera, immune complexes enhanced pDC-derived
IFN-α were more clearly visible with statistical differences
at serum dilutions up to 4 log10. We concluded that com-
plement is not required for the enhancement of IFN-α by
immune-serum, and heat-labile serum factors could even
have a suppressive effect. Considering this, all further
experiments were performed with heat-treated serum.FMDV and immune complexes activate pDC through the
TLR7 pathway
Our previous work demonstrated that FMDV immune
complex-mediated pDC activation required live virus and
was associated with expression of non-structural FMDV
proteins. This indicated that a virus replication cycle is
initiated with formation of double stranded RNA, a poten-
tial trigger of IFN-α responses [5]. Although TLR7 is
known to be the main sensor for RNA viruses in pDC, it
represents a receptor for single stranded RNA. We were
therefore interested to determine the role played by TLR7
in sensing FMDV and FMDV immune complexes. To this
end we used the immuno-regulatory sequence 661
(IRS661) representing an ODN inhibitor of TLR7 which
had been previously established for human and murine
immune systems [19]. We employed influenza virus-
stimulated pDC, a known ligand for TLR7 to test the effi-
ciency of IRS661 to inhibit the TLR7 pathway of porcine
pDC. As shown in Figure 5, 0.8–3.3 μM of IRS661 inhib-
ited 60–70% of IFN-α production induced by influenza
virus (Figure 5A). We next tested the ability of IRS661 at a
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Figure 5 FMDV-induced and immune complexe-induced IFN-α
occurs through a TLR7-dependant pathway. A. IFN-α responses
of enriched pDC (CD14-depletion/CD172a-enrichment) stimulated
for 16 h with influenza A virus (PR8) in absence or presence of
different IRS661 (TLR7 inhibitor) or control ODN (Ctrl ODN)
concentrations. B. Impact of IRS661 (0.7 μM) on IFN-α responses
of enriched pDC stimulated with FMDV O UKG 2001
(MOI of 1 TCID50/cell) pre-incubated for 30 min with naïve and
anti-O Manisa sera. After 24 h, IFN-α was quantified by ELISA. The
mean value and the standard deviations of triplicates cultures are
shown. The data are representative of two independent
experiments.
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pDC in presence of IRS661. When FMDV immune com-
plexes were employed IRS661 inhibited pDC responses by
60–80% (Figure 5B). Similar levels of inhibition were also
observed with other FMDV isolates (data not shown). The
control ODN did not influence IFN-α production of
FMDV-stimulated pDC (data not shown).
PDC cultures permit to detect efficient opsonisation of
FMDV in the absence of neutralization
We were next interested to determine whether opsonis-
ing activity can also be detected in the absence of neu-
tralizing activity. To this end, an anti-O Manisa serum
was employed and tested against FMDV O UKG 2001
(NT of 4.1 log10) and against A Brazil 10/93 (NT below
detection limit). Interestingly, despite the inability to
neutralize the A serotype virus, opsonising activity
against both viruses was observed at a similar serum di-






































































Figure 6 Opsonising activity of an anti-O Manisa serum can
occur against a neutralized FMDV strain as well as a non-
neutralized FMDV serotype-A strain. IFN-α responses of enriched
pDC (CD14-depletion/CD172a-enrichment) stimulated with O UKG
2001 (A, B) or A Brazil 10/93 (C, D) pre-incubated with anti-O Manisa
serum (A, C) or naïve serum (B, D). FMDV was used at an MOI of 1
TCID50/cell. Serum was heat-treated, then diluted at the indicated
concentrations and pre-incubated for 30 min at 39°C with the virus.
IFN-α in supernatants was measured by ELISA. Values are shown as
box plots representing of 3-5 independent experiments with each
condition performed in triplicate cultures. The black line represents
the median value and the red line the mean value. The error bars
represent the standard deviation and the dots are outlier values
(5th/95th percentile). Statistical significance (Rank Sum test, P< 0.005)
was calculated between immune and naïve sera employed at the
same dilutions and is indicated by an asterisk. The NT against the
two viruses employed is indicated in log10 of serum dilution.production was reached at the same serum dilution of 3
log10 with both FMDV isolates (Figure 6A). These
experiments were repeated with five different batches of
pDC preparations, and the enhanced IFN-α responses
by the immune serum compared to the effect of naive
serum were consistently observed despite some variabil-
ity in the height of the IFN-α responses (Figures 6B and
6D). Similar results were also obtained with another
serum sample obtained from a second vaccinated pig
(data not shown). Furthermore, both sera were also
able to opsonize A/Turkey/99 confirming the exist-
ence of opsonizing antibodies cross-reacting with other
serotypes.
Considering these surprising results, neutralizing and
opsonising activities of an anti-O Manisa serum were
measured against a collection of FMDV isolates of sero-
types O, A, C and Asia-1 and the results are summarized
in Table 1 as NT and opsonisation titres (OT) represent-
ing the highest serum dilution able to opsonise FMDV
for enhanced IFN-α responses. As expected the immune
serum was only able to neutralize the O serotype viruses
O UKG 2001 and O VietNam 7/97. With these viruses
we found a similar OT of 4 and 3 log10, respectively. As
shown in Figure 6C, D, non-neutralized A Brazil 10/93
could be opsonised to a titre of 4 log10. Also FMDV A
Turkey 99 and Asia-1 Turkey/99, albeit to a lesser ex-
tent, were opsonised although not being neutralized.
Only, C1-Noville was neither neutralized nor opsonised
by an anti-O Manisa serum. These results demonstrate
that opsonisation of FMDV can occur in the absence of
neutralization.
Discussion
PDC are professional sensors of viruses producing large
amount of type-I IFNs. However, in particular non-
enveloped viruses such as FMDV have been shown to be
unable to trigger pDC activation in vitro, unless the cells
are stimulated with immune complexed virus [7,23].
However, in the present study we demonstrate thatTable 1 Relationship between neutralization and
opsonization titres
anti-O Manisa serum
Serotype Viral strain NT in log10 OT* in log10
Type-O O UKG 2001 4.1 4
O VietNam 7/97 3.1 3
Type-A A Brazil 10/93 < 1.5 4
A Turkey/99 < 1.5 2
Type Asia-1 Asia-1 Turkey/99 < 1.5 2
Type-C C1-Noville < 1.5 0
* Opsonizing titres representing minimum serum dilution able to enhance IFN-
α responses by pDC (calculated from 3-5 independent experiments as
described in Figure 6).
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bodies if improved purification methods are employed.
We also demonstrate that both immune-complexed
FMDV and uncomplexed FMDV activate pDC via TLR7.
As expected, the responsiveness of pDC to FMDV is
possible with more pure populations of pDC but our
results also indicate that other factors could be import-
ant such as the percentage of other cell types present in
the cell culture. The observation that in vivo IFN-α
responses occur in the early innate phase of the immune
response of cattle and pigs [24,25] support the idea of an
early activation of pDC by FMDV in absence of specific
antibodies and support the in vivo relevance of our data.
In fact, in cattle it has been demonstrated that pDC are
the source of early IFN-α responses [8].
Our study also demonstrates remarkable differences of
different FMDV isolates to activate pDC. The reason for
the differences in activation of pDC could be either
related to the uptake of the virus by pDC or to the func-
tion of viral genes such as the IFN antagonist Lpro, the
viral proteinase. FMDV interacts with immune and non-
immune cells [26] via Arg-Gly-Asp (RGD)-dependent
and RGD-independent mechanisms, after cell culture
adaptation to heparin sulphate binding [27]. Certainly,
the differences we observed with pDC are not related to
a cell culture adaptation of certain FMDV isolates to
heparin sulphate binding since all viruses employed in
this study had a maximum of three passages. Further-
more, we have compared cell culture adapted heparin-
sulphate binding virus to its non-adapted original
wild-type FMDV (viruses as described in [17]), and found
no differences in the ability to activate pDC (data not
shown). On the other hand, the leader proteinase Lpro
inhibiting the type-I IFN pathway [28], is variable among
serotypes [29] and could contribute to a isolate-specific
FMDV counteraction on the IFN-α induction in pDC.
The potential of some FMDV isolates to consistently in-
duce IFN-α also at low MOIs would support this hy-
pothesis. Overall, it is important to note that in
comparison to the IFN-α levels in response to influenza
viruses [21] and CpG [14], FMDV is a poor stimulator
of pDC. Nevertheless, considering that IFN-α is known
to efficiently inhibit FMDV replication in vitro and
in vivo [22], it is now important to investigate the
relationship of the ability of an FMDV isolate to induce
IFN-α in vitro and to promote in vivo innate and adap-
tive immune responses.
Previous studies have demonstrated that antibody-
dependent internalization of FMDV via the FcγRII
represents an important pathway to enter macrophages
[5] and pDC [7,8]. One of the main objectives of this
study was to determine the relationship between opson-
isation and neutralization. Non-neutralized serotype-A
and Asia-1 isolates could be efficiently opsonised usingan anti-O serum while others were not, such as a sero-
type C isolate. From phylogenetic studies based on VP1
amino acid sequence, which contains the most antigenic
site [30], serotypes O and Asia-1 belong to the same
branch [27]. Serotypes A and C are more distant, par-
tially explaining our findings [27]. Interestingly, this op-
sonisation efficiently occurred with serum dilutions
similar to those required for neutralization, when antige-
nically related viruses from the same serotypes were
employed. This would indicate that the type of
antibodies and their specificities is similar for both func-
tions. However, we also found opsonisation in non-
neutralizing conditions contradicting this idea. It could
be speculated that opsonising activity is possible at lower
avidity compared to neutralization, in which the anti-
body binding to the virus is in competition to virus
binding to the cellular receptor. This competition can
only occur indirectly for opsonisation, since the cellular
FcR will bind to the Fc portion of the antibody. The ob-
servation that opsonisation can occur at similar serum
dilutions with a neutralized and non-neutralized virus
would favour the presence of non-neutralizing epitopes,
which can be conserved between different serotypes.
The answer to these questions needs to be addressed
using monoclonal antibodies rather than a polyclonal
serum such as in the current study.
The broad activity of opsonising antibodies is interest-
ing in the frame of vaccine-induced immune responses.
Non-neutralizing vaccine-induced antibodies could en-
hance innate immune responses against antigenically less
related FMDV challenge strains and restrict their ability
to replicate. Furthermore, other FcR-mediated functions
such as virus phagocytosis and more efficient antigen
presentation of viral antigens to T cells could be pro-
moted. Although this is not sufficient to mediate
complete protection against disease, it could limit virus
replication, the severity of clinical diseases and transmis-
sion within the heard. Future studies are required to de-
termine how such responses correlate to protection
(partial or complete), and if this is the case how vaccines
can be improved to promote broadly reactive antibody
responses able to link innate and adaptive immunity to
FMDV via opsonising antibodies.
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